If 2024 was the year of the German shift, 2026 confirms that Europe has become the great engine of the global medical cannabis market. Trade flows, investment and regulation all point in the same direction: the continent is importing, producing and consuming more therapeutic cannabis than ever.
Germany, the market magnet
Germany’s 2024 reform continues to pull the whole continent along. Canada exported around 240 tonnes in 2025 – more than double the previous year – and Germany accounts for 62% of those flower exports, making it the largest importing market outside North America.
More countries, more frameworks
The regulatory map is moving fast: in January 2026 Czechia authorised growing three plants for personal use, the Netherlands is trialling a closed legal supply chain in ten municipalities, and France and Spain are launching pharmaceutical-style medical frameworks. Medical infrastructure keeps expanding.
Opportunities… and warnings
Growth brings its own risks. Analysts warn of oversupply and downward pressure on prices as cultivation capacity expands, and of possible restrictions on telemedicine in key markets. Pharmaceutical product is gaining ground over flower and the industry’s language is becoming more technical (delta-9, THCa, CBN).
Why it matters for Spannabis B2B
Distribution, import-export, investment and compliance are now the heart of the European cannabis business. Spannabis B2B Bilbao 2027 sits those decision-makers in the same room. Get your ticket or book a B2B table.
Sources: Business of Cannabis; Prohibition Partners; 2026 market reports.